Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

Executive Summary

• Medicenna Therapeutics announced that updated Phase 1/2 ABILITY‑1 clinical data for MDNA11 will be presented at the ESMO Immuno‑Oncology Congress 2025 in London (Dec 10‑12, 2025).
• The presentation will cover interim analysis of MDNA11 as monotherapy and in combination with pembrolizumab in advanced solid tumors.
• A copy of the presentation will be posted on Medicenna’s website after the conference.

Key Details

• Presentation Title: “ABILITY‑1, a phase 1/2 of MDNA11, a next‑generation IL‑2 agonist, alone or with pembrolizumab in advanced solid tumors: interim analysis.”
• Presenter: Dr. André Mansinho, MD MSc, Assistant Professor, Faculty of Medicine, University of Lisbon (principal investigator of the ABILITY‑1 study).
• Date & Venue: December 10, 2025 at the European Society for Medical Oncology (ESMO) Immuno‑Oncology Congress 2025, London, United Kingdom.
• Study Context: Phase 1/2 ABILITY‑1 Study evaluating MDNA11 (a next‑generation IL‑2 agonist) as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
• Post‑Event Access: A copy of the presentation will be made available on Medicenna’s “Events and Presentations” web page after the congress concludes.

Notable Quotes

(No direct quotes were provided in the release.)